Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

117.00
+1.571.36%
Post-market: 117.000.00000.00%19:30 EDT
Volume:734.30K
Turnover:86.16M
Market Cap:9.73B
PE:-36.42
High:119.63
Open:116.05
Low:114.35
Close:115.43
52wk High:130.05
52wk Low:43.74
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.10
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.45
PE(LYR):-31.71

Loading ...

Kymera Therapeutics Inc : Mizuho Raises Target Price to $140 from $120

THOMSON REUTERS
·
Jul 16

Kymera Therapeutics Shares Fall After RBC Downgrade

MT Newswires Live
·
Jul 14

Kymera Therapeutics Cut to Sector Perform from Outperform by RBC Capital

Dow Jones
·
Jul 13

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

MT Newswires Live
·
Jul 13

Kymera Therapeutics Inc : RBC Cuts to Sector Perform from Outperform; Raises Target Price to $115 from $106

THOMSON REUTERS
·
Jul 13

Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?

Simply Wall St.
·
Jul 11

Kymera CEO Nello Mainolfi Disposes of USD 5.95 Million in Common Shares

Reuters
·
Jul 08

Kymera Therapeutics Appoints Elizabeth Laws as SVP, Kt-621 Development Program Leader

Reuters
·
Jul 07

Kymera Therapeutics Appoints Elizabeth Laws, Ph.d., as Senior Vice President, Global Program Team Leader for Kt-621, First-in-class, Oral Stat6 Degrader

THOMSON REUTERS
·
Jul 07

German Pension Reform Turns Savers into Investors. That Will Fuel the Market. 13D Filings

Dow Jones
·
Jul 03

Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run

Simply Wall St.
·
Jul 03

Kymera CFO Bruce Jacobs Sells USD 8.67 Million in Common Shares

Reuters
·
Jul 03

Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?

Simply Wall St.
·
Jul 01

Kymera Therapeutics Director Bruce Booth Reports $57.91 Million Common Share Disposal

Reuters
·
Jul 01

Kymera Therapeutics is Maintained at Buy by B of a Securities

Dow Jones
·
Jun 30

Kymera Therapeutics price target raised to $125 from $110 at BofA

TIPRANKS
·
Jun 30

Kymera Therapeutics is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jun 29

B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating

MT Newswires Live
·
Jun 29

Kymera Therapeutics Inc : Truist Securities Raises Target Price to $136 from $116

THOMSON REUTERS
·
Jun 29